XBIO - Xenetic Biosciences Inc logo

Xenetic Biosciences Inc

XBIO

Xenetic Biosciences develops biopharmaceuticals targeting oncology, focusing on immune-oncology technologies and cell-based therapies. Its pipeline includes treatments for pancreatic carcinoma, solid tumors, and anemia in chronic kidney disease.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$3today

Score Overview

1 Year
Score
Net Growth7.68%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth9.55%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.1
Net Growth56.16%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth180.93%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth95.43%
Net Trend70%
Net Income Consistency
Rev Growth8.69%
Rev Trend75%
Revenue Consistency
All Time
Scoreโ€”
Net Growth82.70%
Net Trend67%
Net Income Consistency
Rev Growthโ€”
Rev Trend70%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Xenetic Biosciences Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. XBIO does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 1.72โ€”
1 Year2025-10-23
$ 3.86-55.44%
5 Years2021-10-22
$ 16.95-89.85%
10 Years2016-10-18
$ 528.00-99.67%
All Time2014-06-30
$ 3.05K-99.94%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 3M-$ 2M$ 6M
2025$ 2M-$ 2M$ 7M
2024$ 2M-$ 3M$ 6M
2023$ 2M-$ 4M$ 8M
2022$ 1M-$ 6M$ 13M
2021$ 1M-$ 5M$ 18M
2020$ 436.94K-$ 10M$ 11M
2019-$ 12M$ 10M
2018$ 0.00-$ 7M$ 571.61K
2017$ 7M-$ 3M$ 5M
2016$ 3M-$ 54M$ 4M
2015$ 0.00-$ 12M$ 132.23K
IPO2014$ 0.00-$ 14M$ 2M
XBIO - Xenetic Biosciences Inc logo

Xenetic Biosciences Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 436.94K to $ 2M and net income went from -$ 10M to -$ 2M. Revenue increased in 4 of those 5 years; net income in 4.

Between 2015 and 2025, revenue grew from $ 0.00 to $ 2M and net income went from -$ 12M to -$ 2M. Revenue increased in 8 of those 10 years; net income in 7.

Xenetic Biosciences Inc currently holds a 5-year HDB Score of 7.1 out of 10. How the HDB Score is calculated.

Membership

Explore XBIO with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies